SemBioSys - Heart Attack and Stroke

By: Sembiosys  09-12-2011
Keywords: Cardiovascular Disease, Genetically Engineered

The Problem

Cardiovascular diseases, including heart attack and stroke, are the leading causes of mortality in developed nations and by 2010, are projected to become the leading cause of mortality worldwide.

Current treatments are generally only able to halt the progression of plaque buildup in blood vessels, the cause of cardiovascular disease. However, a new class of drugs, most notably Apo AIMilano, has been shown to actually reduce plaque size.

Apo AI is the major protein associated with high density lipoprotein (HDL), or "good cholesterol", whose function is to remove excess cholesterol from arteries. Variants of this protein, specifically Apo AIMilano, have demonstrated the ability to cause atherosclerotic plaque regression. Based on clinical results, patients will require large doses of Apo AIMilano per treatment. High doses, combined with the millions of patients that could benefit from this treatment, creates an enormous potential demand for these compounds. Current production systems have critical manufacturing barriers and appear unable to meet this demand.

Our Solution

To solve the manufacturing and dosing challenges, SemBioSys is producing Apo AIMilano in genetically engineered safflower. We believe that plants may be the only cost-effective production vehicle for these life-saving drugs.

What We Have Accomplished

We have successfully achieved commercial levels of Apo AIMilano accumulation in safflower and have demonstrated biologic activity in 7 preclinical models. Consistent functionality in 2 independent in vivo studies have demonstrated

  • rapid mobilization of cholesterol from the arterial wall;
  • lessening of plaque lipid content;
  • decreased immune reactivity in aortic plaque; and
  • reduction of total plaque volume versus controls.

Data for SemBioSys' Apo AIMilano was presented at the American College of Cardiology's 59th Annual Scientific Session in March 2010.

What We Are Working On

We are seeking with an industry leader in cardiovascular disease to drive the advanced development and commercialization of plant-derived Apo AIMilano.

Keywords: Cardiovascular Disease, Genetically Engineered

Contact Sembiosys

Email - none provided

Print this page

Other products and services from Sembiosys


SemBioSys - In Development

We have also developed an extraction process that we believe will allow for the production of chymosin in plants at significantly lower costs than current production systems. We have chosen to work on products for which the inherent benefits of our technology, including scalability and economics, enable them to be commercially viable.


SemBioSys - Diabetes

We believe our plant-made insulin will offer dramatic reductions in capital and operating costs and provide an accessible source of insulin to meet this exploding demand. Discussions with the US Food and Drug Administration have confirmed that safflower-produced insulin is eligible to follow a shortened drug approval process.


SemBioSys - Personal Care

SemBioSys has developed an all-natural process to extract oilbodies from safflower seeds resulting in a base emulsion with superior hydration, skin conditioning and moisturization properties compared to traditional ingredients such as petrolatum or chemical and animal byproducts. Beyond the benefits as a personal care product ingredient, oilbodies hold the potential to act as a carrier and delivery system for pharmaceutical products.


SemBioSys - Technology

Our technology is built on two basic capabilities: the use of genetic engineering to attach high-value proteins to (the structures used by seeds to store oil); and extraction of oilbodies from seeds in a cost-effective manner. For the production of high-value proteins, we believe that our plant technology is unique among transgenic systems as it addresses both production and purification challenges.


SemBioSys - Overview

The same advantages that drive our pharmaceutical opportunities also apply to our non-pharmaceutical products, which include topical ingredients that are delivering innovation and value for personal care producers, nutritional oils for use in a variety of consumer goods, and applications for agricultural biotechnology.